Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
September 4, 2020updated 14 Sep 2020 2:25pm

Global clinical trials activity decreases 2.9% in Q2 2020

Global clinical trials activity decreased by 2.9% in Q2 2020, when compared with the same quarter in 2019, according to GlobalData.

Industry-sponsored trials accounted for a 46.1% share of overall activity in Q2 2020, an increase of 1.3% when compared with Q2 2019.

Non-industry-sponsored trials accounted for a 53.9% share of all clinical trials in Q2 2020, marking a decrease of 1.3% when compared with the same period in 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Q2 2020 industry-sponsored clinical trials activity by therapy areas

Oncology was the leading therapy area for industry-sponsored clinical trials in Q2 2020, accounting for a 28.3% share of all trials.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

This was followed by infectious disease with a 25.8% share, central nervous system with 10.8%, respiratory with 9.6% and metabolic disorders with 6.6%.

In Q2 2019, oncology led with a 27.9% share, followed by central nervous system with 14.4%, infectious disease with 10.1%, metabolic disorders with 9.4%, and cardiovascular with 8.6%.

Industry-sponsored trials: Q2 2020 vs Q2 2019
Therapy Area Q2 2019 Q2 2020 Activity
Oncology 27.9% 28.3% Increase
Infectious Disease 10.1% 25.8% Increase
Central Nervous System 14.4% 10.8% Decrease
Respiratory 5.5% 9.6% Increase
Metabolic Disorders 9.4% 6.6% Decrease
Cardiovascular 8.6% 6.0% Decrease
Gastrointestinal 7.0% 5.5% Decrease
Immunology 5.9% 4.9% Decrease
Dermatology 4.9% 4.1% Decrease
Genito Urinary System And Sex Hormones 2.7% 2.7% Decrease
Musculoskeletal Disorders 5.3% 2.7% Decrease
Hematological Disorders 3.6% 2.6% Decrease
Ophthalmology 3.0% 2.5% Decrease
Women’s Health 2.4% 1.7% Decrease
Genetic Disorders 1.7% 1.6% Decrease
Male Health 0.6% 1.0% Increase
Ear Nose Throat Disorders 1.1% 0.9% Decrease
Hormonal Disorders 0.8% 0.4% Decrease
Mouth and Dental Disorders 0.7% 0.4% Decrease
Non Malignant Disorders 0.3% 0.2% Decrease
Nutritional Disorders 0.7% 0.2% Decrease

Most active therapy areas in non-industry-sponsored clinical trials

In Q2 2020 the leading therapy area for non-industry-sponsored clinical trials was infectious disease, accounting for a 34.9% share of all trials.

This was followed by oncology with a 20.0% share, central nervous system with 16.3%, respiratory with 10.1%, and cardiovascular with 7.0%.

In Q2 2019, central nervous system held the lead in non-industry-sponsored clinical trials with a 26.0% share, followed by oncology with 19.8%, cardiovascular with 9.6%, metabolic disorders with 7.8%, and gastrointestinal with 7.7%.

Non-Industry-sponsored trials: Q2 2020 vs Q2 2019
Therapy Area Q2 2019 Q2 2020 Activity
Infectious Disease 7.3% 34.9% Increase
Oncology 19.8% 20.0% Increase
Central Nervous System 26.0% 16.3% Decrease
Respiratory 3.9% 10.1% Increase
Cardiovascular 9.6% 7.0% Decrease
Gastrointestinal 7.7% 5.4% Decrease
Metabolic Disorders 7.8% 4.1% Decrease
Women’s Health 6.3% 4.0% Decrease
Musculoskeletal Disorders 5.7% 3.6% Decrease
Immunology 2.9% 2.9% Decrease
Hematological Disorders 3.3% 2.7% Decrease
Genito Urinary System And Sex Hormones 3.6% 2.2% Decrease
Dermatology 3.2% 2.1% Decrease
Mouth and Dental Disorders 2.6% 1.4% Decrease
Ear Nose Throat Disorders 1.4% 1.1% Decrease
Ophthalmology 2.0% 1.1% Decrease
Genetic Disorders 0.7% 0.7% Decrease
Nutritional Disorders 0.7% 0.5% Decrease
Male Health 1.0% 0.4% Decrease
Hormonal Disorders 1.2% 0.3% Decrease
Non Malignant Disorders 0.5% 0.3% Decrease

Asia-Pacific region has the most activity for industry-sponsored clinical trials

Asia-Pacific was the most active region for industry-sponsored clinical trials activity in Q2 2020 with a 47.9% share, compared with 52.0% in Q2 2019.

North America was the second most active region with a 34.7% share in Q2 2020, up from 33.3% in Q2 2019, followed by Europe with a 28.0% share in Q2 2020, down from 29.2% in Q2 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 85.4% share in industry-sponsored clinical trials in Q2 2020, compared with 84.1% in Q2 2019. Multinational trials accounted for 14.6% in Q2 2020, against 15.9% in Q2 2019.

Regional activity for non-industry-sponsored clinical trials

Asia-Pacific saw the most non-industry-sponsored clinical trial activity in Q2 2020 with a 41.0% share, down from 54.4% in Q2 2019.

Middle East and Africa held the second position with a 19.9% share in Q2 2020, compared with 16.1% in Q2 2019. This was followed by North America with a 19.9% share in Q2 2020, as against 16.4% in Q2 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies accounted for 98.8% share of non-industry-sponsored clinical trials in Q2 2020, compared with 98.9% in Q2 2019. Multinational trials accounted for a 1.2% share in Q2 2020, up from 1.1% in Q2 2019.

Clinical trials by phase in Q2 2020

Phase II trials outnumbered all other studies with a 39.5% share for industry-sponsored trials in Q2 2020, compared with 33.8% in Q2 2019.

The share of Phase I trials stood at 30.0% in Q2 2020, down from 37.2% in Q2 2019. Phase III trials increased to 20.0% in Q2 2020, compared with 17.2% in Q2 2019, followed by Phase IV trials with a 10.5% share in Q2 2020, against 11.8% in Q2 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

For non-industry-sponsored clinical trials, Phase II activity decreased to a 43.7% share in Q2 2020, compared with 47.7% in Q2 2019.

Phase III trials were the second most active with a 23.8% share in Q2 2020, compared with 18.7% in Q2 2019. Phase IV trials held an 18.1% share in Q2 2020, against 19.5% in Q2 2019, followed by Phase I trials with a 14.5% share in Q2 2020, over 14.1% in Q2 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU